Low clinical sensitivity and unexpectedly high incidence for neuropathologically diagnosed progressive supranuclear palsy
- PMID: 37040756
- PMCID: PMC10117158
- DOI: 10.1093/jnen/nlad025
Low clinical sensitivity and unexpectedly high incidence for neuropathologically diagnosed progressive supranuclear palsy
Abstract
The objective of this study was to determine the prevalence, incidence, and clinical diagnostic accuracy for neuropathologically diagnosed progressive supranuclear palsy (PSP) with data from a longitudinal clinicopathological study using Rainwater criteria to define neuropathological PSP. Of 954 autopsy cases, 101 met Rainwater criteria for the neuropathologic diagnosis of PSP. Of these, 87 were termed clinicopathological PSP as they also had either dementia or parkinsonism or both. The prevalence of clinicopathologically defined PSP subjects in the entire autopsy dataset was 9.1%, while the incidence rate was estimated at 780 per 100 000 persons per year, roughly 50-fold greater than most previous clinically determined PSP incidence estimates. A clinical diagnosis of PSP was 99.6% specific but only 9.2% sensitive based on first examination, and 99.3% specific and 20.7% sensitive based on the final clinical exam. Of the clinicopathologically defined PSP cases, 35/87 (∼40%) had no form of parkinsonism at first assessment, while this decreased to 18/83 (21.7%) at final assessment. Our study confirms a high specificity but low sensitivity for the clinical diagnosis of PSP. The low clinical sensitivity for PSP is likely primarily responsible for previous underestimates of the PSP population incidence rate.
Keywords: Autopsy; Dementia; Diagnosis; Neuropathology; Parkinsonism; Tau; Tufted astrocyte.
© The Author(s) 2023. Published by Oxford University Press on behalf of American Association of Neuropathologists, Inc. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Conflict of interest statement
H.A.S. reports receiving research support in the past 12 months from Transposon Therapeutics, Saccadous Inc, NINDS/NIH, Jazz Pharmaceuticals, Supernus, Parkinson’s Foundation and Barrow Neurological Foundation and consulting honoraria from AbbVie and the Tremor Research Group. S.H.M. reports consulting relationships with AbbVie and Sunovion in the past 12 months. A.A. reports receiving honoraria or support for consulting; participating in independent data safety monitoring boards; providing educational lectures, programs, and materials; travel, or serving on advisory boards for Acadia, Alzheimer’s Association, Alzheimer’s Disease International, Biogen, Eisai, Lundbeck, Roche/Genentech, Novo Nordisk, and Qynapse. Book royalties from Oxford University Press for a medical book on dementia. Institutional research grant/contract funding from AZ DHS CTR040636, the Foundation for NIH, Washington University St Louis, and Gates Ventures. C.H.A. reports consulting for Avion, Cionic, CND Life Sciences, Jazz Pharmaceuticals, and XW Pharma. The other authors report no additional disclosures or conflicts of interest.
Figures
References
-
- Steele JC, Richardson JC, Olszewski J; Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964;10:333–59 - PubMed
-
- Hauw JJ, Daniel SE, Dickson D, et al.Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994;44:2015–19 - PubMed
-
- Litvan I, Hauw JJ, Bartko JJ, et al.Validity and reliability of the preliminary NINS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 1996;55:97–105 - PubMed
-
- Litvan I, Agid Y, Calne D, et al.Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP International Workshop. Neurology 1996;47:1–9 - PubMed
-
- Josephs KA, Dickson DW.. Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. Mov Disord 2003;18:1018–26 - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
